C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac. 21442.
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Klimstra D, Franceschi D, Tao Y, Fortner J, Blumgart L, Brennan M. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169:28–34. discussion −5.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–s16.
   PubMed Web of Science ®Google Scholar
• Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, et al. 2008. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 47:1025–1037. doi:10.1002/gcc.20604.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, et al. 2018. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 17:45. doi:10.1186/s12943-018-0796-y.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–804.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. 1989. Molecular cloning and expression of human hepatocyte growth factor. Nature. 342:440–443. doi:10.1038/342440a0.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S, von Pawel J. 2013. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 39:793–801. doi:10.1016/j.ctrv.2013.02.001.
   PubMed Web of Science ®Google Scholar
• Cui JJ. 2014. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 57:4427–4453. doi:10.1021/jm401427c.
   PubMed Web of Science ®Google Scholar
• Jung KH, Park BH, Hong SS. 2012. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res. 35:595–604. doi:10.1007/s12272-012-0402-6.
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim H. 2017. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy. Exp Mol Med. 49:e307. doi:10.1038/emm.2017.17.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, et al. 2017. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1467–1482. doi:10.1016/s1470-2045(17)30566-1.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, et al. 2018. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 379:54–63. doi:10.1056/NEJMoa1717002.
   PubMed Web of Science ®Google Scholar
• Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, et al. 2004. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol. 41:267–273. doi:10.1016/j.jhep.2004.04.013.
   PubMed Web of Science ®Google Scholar
• Whittaker S, Marais R, Zhu AX. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 29:4989–5005. doi:10.1038/onc.2010.236.
   PubMed Web of Science ®Google Scholar
• Araste F, Abnous K, Hashemi M, Taghdisi SM, Ramezani M, Alibolandi M. 2018. Peptide-based targeted therapeutics: focus on cancer treatment. J Control Release. 292:141–162. doi:10.1016/j.jconrel.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Farzaneh Behelgardi M, Zahri S, Mashayekhi F, Mansouri K, Asghari SM. 2018. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis. Sci Rep. 8:17924. doi:10.1038/s41598-018-36394-0.
   PubMed Web of Science ®Google Scholar
• Stoker M, Gherardi E, Perryman M, Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 327:239–242. doi:10.1038/327239a0.
   PubMed Web of Science ®Google Scholar
• Giacomin A, Sergio A, Vanin V, Gazzola A, Cazzagon N, Farinati F. 2012. Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges. Dig Dis. 30:284–288. doi:10.1159/000336993.
   PubMed Web of Science ®Google Scholar
• Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, Gao CF. 2004. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene. 23:5193–5202. doi:10.1038/sj.onc.1207646.
   PubMed Web of Science ®Google Scholar
• Arriola E, Canadas I, Arumi-Uria M, Domine M, Lopez-Vilarino JA, Arpi O, Salido M, Menéndez S, Grande E, Hirsch FR, et al. 2011. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105:814–823. doi:10.1038/bjc.2011.298.
   PubMed Web of Science ®Google Scholar
• Ogasawara H, Hiramoto J, Takahashi M, Shirahama K, Furusaka A, Hiyane S, Nakada T, Nagayama K, Tanaka T. Hepatocyte growth factor stimulates DNA synthesis in rat preneoplastic hepatocytes but not in liver carcinoma cells. Gastroenterology. 1998;114:775–781.
   PubMed Web of Science ®Google Scholar
• von Schweinitz D, Faundez A, Teichmann B, Birnbaum T, Koch A, Hecker H, Glüer S, Fuchs J, Pietsch T. 2000. Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer. 85:151–159. doi:10.1002/(SICI)1097-0215(20000115)85:2<151::AID-IJC1>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13:41–59.
   PubMed Web of Science ®Google Scholar
• Gallego MI, Bierie B, Hennighausen L. 2003. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22:8498–8508. doi:10.1038/sj.onc.1207063.
   PubMed Web of Science ®Google Scholar
• Goyal L, Muzumdar MD, Zhu AX. 2013. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 19:2310–2318. doi:10.1158/1078-0432.CCR-12-2791.
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. 2006. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 6:637–645. doi:10.1038/nrc1912.
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Vande Woude G. 2008. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 18:87–96. doi:10.1016/j.gde.2008.02.001.
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. 2008. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7:504–516. doi:10.1038/nrd2530.
   PubMed Web of Science ®Google Scholar
• Chen L, Li C, Zhu Y. 2015. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy. Oncotarget. 6:30088–30101. doi:10.18632/oncotarget.3937.
   PubMedGoogle Scholar
• Garcia-Vilas JA, Medina MA. 2018. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol. 24:3695–3708. doi:10.3748/wjg.v24.i33.3695.
   PubMed Web of Science ®Google Scholar
• Barbara S, Klaudia S, Marcin M. 2017. Targeting MET receptor in rhabdomyosarcoma: rationale and progress. Curr Drug Targets. 18:98–107. doi:10.2174/1389450117666151209124123.
   PubMed Web of Science ®Google Scholar
• Ponzetto C, Bardelli A, Zhen Z, Maina F, Dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77:261–271.
   PubMed Web of Science ®Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. 2006. New therapies for hepatocellular carcinoma. Oncogene. 25:3866–3884. doi:10.1038/sj.onc.1209550.
   PubMed Web of Science ®Google Scholar
• Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chemi Anti-cancer Agents. 2005;5:575–589.
   PubMedGoogle Scholar
• Wortzel I, Seger R. 2011. The ERK Cascade: distinct Functions within Various Subcellular Organelles. Genes Cancer. 2:195–209. doi:10.1177/1947601911407328.
   PubMedGoogle Scholar
• Sridhar SS, Hedley D, Siu LL. 2005. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 4:677–685. doi:10.1158/1535-7163.mct-04-0297.
   PubMed Web of Science ®Google Scholar
• Tan H, Huang Y, Xu J, Chen B, Zhang P, Ye Z, Liang S, Xiao L, Liu Z. 2017. Spider toxin peptide lycosin-i functionalized gold nanoparticles for in vivo tumor targeting and therapy. Theranostics. 7:3168–3178. doi:10.7150/thno.19780.
   PubMed Web of Science ®Google Scholar
• Du Q, Jiang L, Wang XQ, Pan W, She FF, Chen YL. Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma. Asian Pac J Cancer Prev. 2014;15:3747–3752.
   PubMedGoogle Scholar
• Sartori Balbinot R, Facco Muscope AL, Dal Castel M, Sartori Balbinot S, Angelo Balbinot R, Soldera J. 2017. Intraparenchymal hemorrhage due to brain metastasis of hepatocellular carcinoma. Case Rep Gastroenterol. 11:516–525. doi:10.1159/000479221.
   PubMedGoogle Scholar
• Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, Weitz J. 2011. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 253:453–469. doi:10.1097/SLA.0b013e31820d944f.
   PubMed Web of Science ®Google Scholar
• Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y, Sugawara Y, Makuuchi M. 2009. Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg. 144:46–51. doi:10.1001/archsurg.2008.511.
   PubMedGoogle Scholar